The aging population is growing rapidly. For the first time ever, Canadian seniors outnumbered young adults in 2016. Aging is associated with many physical and metabolic deteriorations including the loss of muscle mass and strength, insulin resistance, increased inflammation and oxidative stress.
The muscles of our bodies are composed of proteins and proteins are made of small building blocks called amino acids. Our bodies have the ability to make some amino acids which are called the non-essential amino acids. However, there are certain amino acids that our body's need to make protein but can only be supplied from the foods that we consume. These are called essential amino acids. Tryptophan is one of the essential amino acids that the body needs. Tryptophan is required for protein synthesis and acts as a precursor for serotonin and nicotinic acid. Therefore, there may be a need for more threonine in the diet of older adults. However, the current requirement for threonine is based on studies conducted exclusively in young adults. Thus, the purpose of this study is to find out how much tryptophan older adults need.

Start Date01 Jun 2024

Sponsor / Collaborator

The Hospital for Sick Children

[+1]

ChiCTR2400081970 / RecruitingNot ApplicableIIT

Study of csDMARDs combined with L-tryptophan supplementation (L-Tryptophan) in the treatment of rheumatoid arthritis

Start Date13 Nov 2023

Sponsor / Collaborator-

DRKS00024510 / RecruitingNot ApplicableIIT

Atopic Dermatitis - novel functions of TRP channels in neuro immune interaction mechanism - TRP channels

Start Date01 Feb 2023

Sponsor / Collaborator-

100 Clinical Results associated with Tryptophan

100 Translational Medicine associated with Tryptophan

100 Patents (Medical) associated with Tryptophan

14,649

Literatures (Medical) associated with Tryptophan

01 Jun 2025·Neural Regeneration Research

Dip2a regulates stress susceptibility in the basolateral amygdala

Article

Author: Chai, Weitai ; He, Xiaoxiao ; Zhu, Xiaojuan ; He, Zixuan ; Tian, Meng ; Yu, Huali ; Li, Jing

JOURNAL/nrgr/04.03/01300535-202506000-00025/figure1/v/2024-08-08T040853Z/r/image-tiff Dysregulation of neurotransmitter metabolism in the central nervous system contributes to mood disorders such as depression, anxiety, and post–traumatic stress disorder. Monoamines and amino acids are important types of neurotransmitters. Our previous results have shown that disco-interacting protein 2 homolog A (Dip2a) knockout mice exhibit brain development disorders and abnormal amino acid metabolism in serum. This suggests that DIP2A is involved in the metabolism of amino acid–associated neurotransmitters. Therefore, we performed targeted neurotransmitter metabolomics analysis and found that Dip2a deficiency caused abnormal metabolism of tryptophan and thyroxine in the basolateral amygdala and medial prefrontal cortex. In addition, acute restraint stress induced a decrease in 5-hydroxytryptamine in the basolateral amygdala. Additionally, Dip2a was abundantly expressed in excitatory neurons of the basolateral amygdala, and deletion of Dip2a in these neurons resulted in hopelessness-like behavior in the tail suspension test. Altogether, these findings demonstrate that DIP2A in the basolateral amygdala may be involved in the regulation of stress susceptibility. This provides critical evidence implicating a role of DIP2A in affective disorders.

01 Feb 2025·Food Chemistry

Cuprospinel decorated biopolymer functionalized CNFs based electrocatalytic platform integrated with grid search optimized neural network for detection of vital amino acid in beverages

Article

Author: Al-Saidi, Hamed M. ; Sebastian, Neethu ; Balram, Deepak ; Alharthi, Salman S ; Al-Saidi, Hamed M ; Yu, Wan-Chin ; Alharthi, Salman S.

An electrocatalytic platform based on a novel nanocomposite integrated with a grid search-optimized neural network (GSNN) was proposed for intelligent sensing of tryptophan. The cuprospinel-decorated chitosan-functionalized carbon nanofibers (CuFe₂O₄/Chit-CNFs) fabricated on a disposable electrode revealed exceptional electrocatalytic activity with a low detection limit (2 nM) and good sensitivity (79.18 μAμM^-1 cm^-2) over a broad linear range (0.05-152.55 μM). Cyclic voltammetry and differential pulse voltammetry were employed, and the sensing mechanism of tryptophan entails its electrocatalytic oxidation, where the synergistic impact of CuFe₂O₄ and Chit-CNFs boosts electrochemical response owing to their high surface area and conductivity. GSNN-based intelligent sensing returned a root mean square error (RMSE) of 2.76 and a mean absolute error (MAE) of 1.12. Moreover, the sensor's performance was tested on samples from apple juice, tomato juice, pineapple juice, and milk for assessing practicality, demonstrating recovery between 96.93 and 101.06 % and maximum relative standard deviation of 2.63 %. The proposed sensor showcased excellent selectivity, repeatability, reproducibility, and stability.

01 Feb 2025·Food Hydrocolloids

Colloidal nanoparticles of a β-cyclodextrin/L-Tryptophan inclusion complex for use as Pickering emulsion stabilizers

Article

Author: Abbaspourrad, Alireza ; Wang, Junyi ; Khazdooz, Leila ; Uyar, Tamer ; Dong, Hongmin ; Dadmohammadi, Younas ; Zarei, Amin

Inclusion complexes of β-cyclodextrin (β-CD) and tryptophan (Trp) were synthesized using an antisolvent approach, and fully characterized. Scanning electron microscope images proved the formation of the β-CD/Trp NPs and the powder X-ray diffraction pattern indicated the formation of a crystalline channel-like structure for the β-CD/Trp nanoparticles (NPs). The NPs of a β-CD/Trp inclusion complex were used as a natural stabilizer at the oil/water interface of a Pickering emulsion. Pickering emulsions with an oil to water ratio of 1:1 (v:v) were obtained under high-speed homogenization and different mass ratios of the β-CD to Trp (1:0, 1:0.1, 1:0.25, 1:0.5, 1:1), and at different pH levels (3, 5, 7, 9). At pH 9, when the β-CD:Trp mass ratio was 1:0.1, the β-CD/Trp NPs were hydrophilic, and the oil-in-water Pickering emulsions stabilized by those nanoparticles showed the highest storage stability: 180 days at room temperature. In contrast, when the emulsions were prepared at pH 5 with the weight ratios of either 1:0.1 or 1:1, β-CD:Trp, the nanoparticles were hydrophobic and could be used to stabilize water-in-oil Pickering emulsions.

News (Medical) associated with Tryptophan

30 Sep 2024

·www.prnewswire.com

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melastatin-3 (TRPM3) antagonist— a novel, highly selective, and non-opioid investigational treatment being developed for migraine and other pain disorders Despite recent treatment advances, migraine remains a leading cause of disability and burden, impacting 40 million people in the US and 1 billion world-wide NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced today that it has initiated a pivotal Phase 2 study of the potential first-in-class, orally administered TRPM3 antagonist, BHV-2100, in the acute treatment of migraine. Continue Reading Richard B. Lipton, M.D. Richard B. Lipton, M.D., the Edwin S. Lowe Professor and Vice Chair of Neurology at the Albert Einstein College of Medicine, and Director of the Montefiore Headache Center commented, "The burden of migraine remains high, and many patients experience inadequate relief or suffer from tolerability issues from existing therapies. There remains a need for novel treatments for migraine to lessen disease burden and disability. The TRPM3 ion channel has been implicated in the pathophysiology of migraine, and this trial is the first to assess efficacy and tolerability of a novel agent targeting this mechanism in migraine." The pivotal Phase 2 study is a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of two doses (75 mg and 150 mg) of BHV-2100 in the acute treatment of migraine. The trial is designed to support registration with FDA-accepted coprimary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours. The trial will enroll approximately 575 patients across 60 sites in the United States. Additional information can be found at . Beth Emerson, M.D., M.B.A., Executive Medical Director and Development Lead for Migraine at Biohaven, stated "Biohaven remains extremely committed to advancing novel therapeutic options for people suffering from migraine. Building on our deep passion, unparalleled expertise, and successful track record of developing innovative medications that are currently making a difference for migraine patients today, our team is thrilled to embark on this important program to potentially deliver a new, cutting-edge therapy for migraine. This includes a large number of patients who do not respond to existing therapies, estimated to be approximately one-third of the 40 million patients in the US who desperately need more treatment options." BHV-2100 is a potentially first-in-class, potent, selective, orally administered TRPM3 antagonist— a novel, non-sedating non-opioid treatment for migraine and pain. BHV-2100 demonstrated excellent safety and tolerability across all doses tested in Phase 1 trials in healthy adults, without the thermoregulatory adverse events observed with other TRP antagonists or sedation associated with other pain medications. Additionally, the pharmacokinetic profile is very well-suited for use in the treatment of acute migraine. Single doses of BHV-2100 demonstrated rapid absorption and sustained concentrations above predicted efficacious levels at all doses tested after 20 minutes with maximal drug concentrations achieved at approximately 1.5 to 2 hours and a half-life of approximately 8-12 hours. Beth Morris, Vice President of Biohaven Clinical Operations, added "Biohaven has deep expertise in running clinical trials in migraine and this study will assess an important new potential therapy for patients. I am proud of our clinical operations team for efficiently advancing this trial into Phase 2 after completing the initial Phase 1 trial earlier this year. Days matter for patients and if this study is positive, we will be one step closer to delivering another novel treatment option to better meet the needs of people with migraine: to resolve symptoms and to return to their lives quickly." About Biohaven Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visit . Forward-looking Statements This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first-in-class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Contact: Jennifer Porcelli Vice President, Investor Relations [email protected] +1 (201) 248-0741 Media Contact: Mike Beyer Sam Brown Inc. [email protected] +1 (312) 961-2502 SOURCE Biohaven Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Phase 2Clinical Result

29 Jul 2024

·www.prnewswire.com

HKBU develops new approach for accurate and efficient inspection of sulfur-treated food and Chinese herbal medicines

HONG KONG, July 29, 2024 /PRNewswire/ -- A research team at Hong Kong Baptist University (HKBU) has developed a new approach for the inspection of sulfur-treated food and Chinese herbal medicinal products through a new chemical marker called tryptophan sulfonate. This approach is more accurate, rapid and efficient for large sample quantities compared to the current testing method. The study marks a potential advancement in food safety and quality assurance, providing the industry with a robust tool for inspecting sulfur-treated food and Chinese herbal medicinal products. Continue Reading Dr Xu Jun, Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine (left), and Mr Chan Kam-chun, Senior Research Assistant of HKBU (right), have developed a tryptophan sulfonate test which can inspect sulfur-treated food and Chinese herbal medicine more accurately and rapidly. The research findings have been published in the international scientific journal Food Chemistry. More accurate and efficient test in need Sulfur treatment, including sulfur fumigation and the addition of sulfites, is a common preservation method employed in the food and Chinese herbal medicinal industries. However, excessive consumption of preservative sulfites in food and Chinese herbal medicinal products can lead to respiratory symptoms and compromised nutritional value and safety. Currently, sulfite test is the most commonly used method for inspecting residual sulfites in sulfur-treated food. Nevertheless, sulfites are chemically unstable, sometimes leading to inaccurate results. Sulfite test is also labour-intensive and time consuming. It can only analyse one sample at a time, making high-throughput analysis challenging. Furthermore, sulfite test may yield false-positive results for food rich in endogenous sulfur-containing components such as garlic and onion. Tryptophan sulfonate as a chemical marker In search of a more accurate and efficient testing approach, Dr Xu Jun , Assistant Professor of the Teaching and Research Division of the School of Chinese Medicine at HKBU, and his research team identified a chemical compound called tryptophan sulfonate in sulfur-fumigated samples using untargeted metabolomics. Tryptophan sulfonate is formed when tryptophan, a naturally occurring amino acid in many foods, reacts with sulfite. The research team conducted comparative experiments on 20 food products using the tryptophan sulfonate test. It was found that tryptophan sulfonate is present consistently in all sulfur-fumigated food samples but not in non-fumigated samples. The finding demonstrated the potential of tryptophan sulfonate as a specific chemical marker for distinguishing sulfur-treated and non-sulfur-treated food products. Tryptophan sulfonate test outperforms sulfite test To evaluate the applicability of tryptophan sulfonate in the inspection of sulfur-treated food products and Chinese herbal medicines, the team applied tryptophan sulfonate and sulfite tests to 50 food and Chinese herbal medicinesamples collected from markets. It was found that tryptophan sulfonate test and sulfite test results were mostly identical except for six food samples, including corn starch, dried star fruit, dried mango, snow fungus, garlic and onion. The tryptophan sulfonate test result was positive in corn starch, dried star fruit, dried mango and snow fungus, but negative in garlic and onion; sulfite test yielded opposite results. As garlic and onion are known to contain endogenous sulfur-containing components, it is evident that the positive sulfite test result is not a consequence of sulfur-treatment. Tryptophan sulfonate test is therefore a more reliable approach for detecting sulfur-treatment for food items with intrinsic sulfur-containing constituents. False-negative due to instability of sulfites For the discrepancies between the two tests on the other four food samples, the research team hypothesised that the sulfite test may produce false-negative results due to the instability of sulfites caused by high temperature and prolonged storage of the food samples. In a separate experiment, the research team found that sulfite levels in sulfur-fumigated ginger, yam and ginseng declined by around 90% to 100% after nine months of storage, and reduced by around 50% to 72% after heating, while the tryptophan sulfonate levels remained stable. They concluded that the instability of residual sulfites could lead to false-negative results. In contrast, tryptophan sulfonate exhibited greater stability over heat and storage, suggesting it serves as a better chemical marker for sulfur-treatment inspection. High throughput screening made possible On the testing procedure, tryptophan sulfonate test is faster and more automated. It involves a direct ultrasonic extraction for one hour and mass spectrometry analysis for two minutes, allowing the parallel handling of batches of samples. In contrast, sulfite test requires 2.5 hours of manual operation, including reflux extraction and titration for a single sample test. Dr Xu Jun said: "Our research showed that tryptophan sulfonate serves as a highly distinctive chemical marker, enhancing the accuracy and efficiency of sulfur-treated food and Chinese herbal medicine inspection. It is especially suitable for high throughput screening of large samples size. It demonstrates the potential in offering a more cost-effective alternative for the existing test protocol adopted by the industry." Moving forward, the research team hopes to further develop the tryptophan sulfonate test for commercial application. SOURCE Hong Kong Baptist University

Clinical ResultDiagnostic Reagents

02 Jul 2024

·www.prnewswire.com

Pet Calming Chews Result in Human Panic

Common July 4 Pet Anxiety Treatment Leads to Accidental Overdose MINNEAPOLIS, July 2, 2024 /PRNewswire/ -- Many people use calming chews to relieve their pet's anxiety, especially during the July 4 holiday. Not only can the sound of fireworks scare your pet, but a change in routine or sudden influx of visitors can cause pets great distress. While these supplements can help calm your pet, they can also be dangerous if taken in too great of a quantity. Continue Reading It was anything but relaxing when Elton overdosed on calming chews and had to be rushed to the veterinary hospital for treatment. "I had just moved to a new apartment, and I ran out to do some grocery shopping," explained Jacque Dickson, who lives with her dogs Elton and Chubbs in Greensboro, North Carolina. "My father had recently bought a bottle of calming chews for Chubbs, who can be anxious. The bottle was in an unopened box, but the dogs managed to get into it and consume the entire bottle of more than 160 chews. My first call was to the pet emergency room, and they had me call Pet Poison Helpline before I even left the house." By calling first, the toxicology experts at Pet Poison Helpline were able to start developing a recommended treatment plan based on Elton and Chubbs' individual situations that could be ready when Dickson arrived at the clinic. "After talking with the experts at Pet Poison Helpline, they determined that Chubbs was not in danger because of his size," Dickson explained. "He's a fit cattle dog, but he's 65 pounds. Because Elton is only 10 pounds, they recommended I take him into the hospital for treatment and observation." As soon as Dickson arrived at Carolina Veterinary Specialists in Greensboro, the medical team was ready to start treatment. The Pet Poison Helpline team had determined that Elton had consumed a dangerous level of the product, which contains tryptophan. The toxicologists were concerned with Elton developing hypernatremia due to the number of chews he ingested, potentially causing a fluid shift that results in increased sodium concentrations. There was also a concern for serotonin syndrome to develop, which causes numerous neurologic and cardiovascular signs, due to the amount of L-tryptophan ingested. With this in mind, the specialists at Pet Poison Helpline recommended an antiemetic, electrolyte monitoring, intravenous fluids and monitoring for serotonin syndrome, a condition that happens when there is too much serotonin in the body. "The dedicated team at Carolina Veterinary Specialists took great care of Elton," said Dr. Renee Schmid, a senior veterinary toxicologist and director of Veterinary Medicine at Pet Poison Helpline. "He was closely monitored overnight and went home the next day, where Ms. Dickson could monitor both him and Chubbs for any additional symptoms or changes in behavior." Accidental medication poisoning is only one of the risks facing pets during the July 4 holiday. An even greater threat is pets being terrified by the loud fireworks explosions or getting out of the house and into other dangers such as being hit by a car. Pet Poison Helpline has partnered with AKC Reunite, the nation's largest not for profit pet recovery service, offering its 24/7 toxicology expertise as an optional, unlimited benefit for its members to add to their pet's lifetime protection. "According to AKC Reunite, more pets go missing during the July 4th weekend than any other time of the year," said Dr. Schmid. "To help prevent problems with your pet, AKC Reunite has six tips for protecting your pet this Independence Day." Tip 1: Establish a Place of Sanctuary Make sure your dog or cat always has access to a comfortable, quiet and safe place to get away from the noise. Either a closet, under a piece of furniture or in his crate. Tip 2: Make Toys and Long-Lasting Treats Available Keep toys and long-lasting treats in your pet's safe area to make the area more fun and to provide distractions from loud noises and flashes. Tip 3: Exercise Earlier in the Day is Key Make time to exercise your pet during daylight hours; then, keep them safely indoors before the fireworks begin. Tip 4: Turn Up the Music, but Not Too Loud At dusk, close your windows and curtains and turn on music or the television to muffle the loud noises that accompany social gatherings and the booming thunder from fireworks. Tip 5: Watch Their Body Language: Pets convey fear by shivering, cowering, tucking their tail between the legs, and averting their eyes. Looming over a fearful dog will only make it more anxious; and unless a dog is likely to get hurt it is often best to leave a fearful dog alone because its behavior when scared is uncertain. Overall, you know your pet best, and recognizing the cues they give you through their body language will help to determine the best way to make them as comfortable as possible. "Enjoy the July 4th festivities with your family and friends, but don't forget about your furry loved ones," Dr. Schmid said. "Taking a few precautions can help protect your pet from a variety of dangers." Pet Poison Helpline created Toxin Tails to educate the veterinary community and pet lovers on the many types of poisoning dangers facing pets, both in and out of the home. All the pets highlighted in Toxin Tails have been successfully treated for the poisoning and fully recovered. About Pet Poison Helpline Pet Poison Helpline®, your trusted source for toxicology and pet health advice in times of potential emergency, is available 24 hours, seven days a week for pet owners and veterinary professionals who require assistance treating a potentially poisoned pet. We are an independent, nationally recognized animal poison control center triple licensed by the Boards of Veterinary Medicine, Medicine and Pharmacy providing unmatched professional leadership and expertise. Our veterinarians and board-certified toxicologists provide treatment advice for poisoning cases of all species, including dogs, cats, birds, small mammals, large animals and exotic species. As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $85 per incident includes follow-up consultations for the duration of the case. Based in Minneapolis, Pet Poison Helpline is available in North America by calling 800-213-6680. Additional information can be found online at . Contact: Dr. Renee Schmid Pet Poison Helpline® (952) 806-3803 [email protected] SOURCE Pet Poison Helpline

100 Deals associated with Tryptophan

External Link

KEGG	Wiki	ATC	Drug Bank
D00020	Tryptophan	N06AX02	DB00150

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Progressive pulmonary fibrosis	Phase 2	CN	Shanxi Bethune Hospital	01 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2022	Not Applicable	Non-Small Cell Lung Cancer	14	Taxol-ramucirumab-pembrolizumab (TRP)	emvrjklkip(ckkbzglbbi) = 1 patient developed G3 immune-mediated diarrhea aymvcpfvff (vosvpziprr ) View more	-	10 Sep 2022
ARVO2019	Phase 2	Macular Edema	40	Monthly 0.5 mg intravitreal ranibizumab injections	(ggcddaffla) = idcmwmbqfj veuetzxkuz (ljvkpqhtdx )	-	01 Jul 2019
ARVO2019	Phase 2	Macular Edema	40	Monthly 0.5 mg ranibizumab plus TRP	(ggcddaffla) = betopnayzt veuetzxkuz (ljvkpqhtdx )	-	01 Jul 2019
IEC2019	Not Applicable	Epilepsy TRP metabolism \| astrocytic function	-	Abnormal Tryptophan Metabolism (Standard diet)	drhvaznncl(irmuqxkfrl) = decreased by TRP loading in ddY mice tbzzlzxvsa (mkffkxspei ) View more	Positive	24 Jun 2019
NCT00865202 (CTgov)	Phase 3	Emergence Delirium	301	placebo+L-tryptophan supplementation	uprimehuku(iwyjitiztd) = lffbxdbdyu qwqijhqczq (yntlfvgwnw, kqjfhqycdm - jmbpxopvop) View more	-	01 Jun 2017
ERA2017	Not Applicable	Renal transplant rejection plasma TRP \| plasma KYN \| IDO-activity	695	TRYPTOPHAN	tbiqwyqaoy(tflpenlmie) = wzqdqahbsx gvcmkgaqud (jdycytdbdt, 2.3 - 5.5) View more	Positive	26 May 2017
ERA2017	Not Applicable		695	TRYPTOPHAN	tbiqwyqaoy(tflpenlmie) = zfprztpesy gvcmkgaqud (jdycytdbdt, 1.7 - 2.3) View more	Positive	26 May 2017
ASN2013	Not Applicable	-	-	Tryptophan	siggcqyvzy(ltdgefqqqg) = ohlztvrycs kaddnorqhq (umqqvjmovs ) View more	-	05 Nov 2013
ASN2013	Not Applicable	-	-	Tryptophan	siggcqyvzy(ltdgefqqqg) = dxqukrvdhu kaddnorqhq (umqqvjmovs ) View more	-	05 Nov 2013
not available (ASN2013)	Not Applicable	tryptophan \| kynurenine	30	Tryptophan	gszzbdiryp(jnvcvrzhqr) = ksfrftfikw hhukpieckq (rqqxnryhmw ) View more	Negative	05 Nov 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis